Interdisciplinary GU Cancer Forum 2025, urothelial carcinoma, Metastatic Urothelial Carcinoma, enfortumab vedotin, advanced urothelial carcinoma when enfortumab vedotin, Optimal Sequence of Treatment ...

Building on preclinical work (Hong X, Adv Sci, 2023) demonstrating the antitumor activity of disitamab vedotin (RC48) in HER2-expressing orthotopic bladder cancer models, Dr. Chen and colleagues ...

The tissue damage and anatomical distortion caused by primary prostate cancer treatment are major challenges for surgeons performing salvage surgery.

Molecular docking studies showed significant interaction of S4 with HER2 and Cyclin D1 proteins, suggesting apoptosis via inhibition. To the best of our knowledge, this is the first report of a ...

The gut-bladder axis (GBA), a bidirectional network connecting gastrointestinal and urinary systems, has recently emerged as a pivotal focus in bladder cancer research. Beyond conventional risk ...

TRE-515 is currently in phase 1 clinical trials for solid tumors. The Fast Track designation applies to TRE-515 in combination with radioligand therapy for the treatment of prostate-specific membrane ...

The Funding Continuity Grant was created to ensure that high-quality bladder cancer research—previously peer-reviewed, approved and funded—can move forward without interruption. It comes in addition ...

A recent study in JAMA Network Open found that although trimodal therapy (TMT) improved quality of life for patients with muscle-invasive bladder cancer, it was not as cost-effective as radical ...

Bladder training versus anticholinergics: seven studies (602 participants) investigated the effects of bladder training versus anticholinergic therapy. Bladder training may be more effective than ...